Abstract
The aim of this report is to assess the available evidence on the use of nintedanib inidiopathic pulmonary fibrosis treatment.
Keywords
Nintedanib; Interstitial pneumonia; Assessment
Bibliographic citation
Comitè d’Avaluació de Medicaments d’Ús Hospitalari (CAMUH). Nintedanib (Ofev®) per al tractament de la fibrosi pulmonar idiopàtica. Barcelona: Agència de Qualitat i Avaluació Sanitàries de Catalunya; 2016. (Informes CAMUH).
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/2349This item appears in following collections
The following license files are associated with this item: